Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyFurazolidone
Identification
- Name
- Furazolidone
- Accession Number
- DB00614 (APRD00988)
- Type
- Small Molecule
- Groups
- Approved, Investigational, Vet approved
- Description
A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
- Structure
Structure for DB00614 (Furazolidone)
- Synonyms
- 3-(5'-Nitrofurfuralamino)-2-oxazolidone
- 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone
- 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone
- 3-[(5-Nitrofurylidene)amino]-2-oxazolidone
- 3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone
- 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
- Furazolidona
- Furazolidone
- Furazolidonum
- FZL
- N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone
- N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one
- Nitrofurazolidone
- Nitrofurazolidonum
- External IDs
- USAF EA-1
- International/Other Brands
- Dependal-M (GlaxoSmithKline) / Furoxone (Roberts Laboratories)
- Categories
- Anti-Infective Agents
- Anti-Infective Agents, Local
- Anti-Infective Agents, Urinary
- Antiparasitic Agents
- Antiprotozoals
- Antitrichomonal Agents
- Central Nervous System Depressants
- Enzyme Inhibitors
- Furans
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Monoamine Oxidase Inhibitors
- Nitro Compounds
- Nitrofurans
- Oxazoles
- Oxazolidinones
- Renal Agents
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- UNII
- 5J9CPU3RE0
- CAS number
- 67-45-8
- Weight
- Average: 225.1583
Monoisotopic: 225.038570349 - Chemical Formula
- C8H7N3O5
- InChI Key
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N
- InChI
- InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
- IUPAC Name
- 3-{[(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one
- SMILES
- [O-][N+](=O)C1=CC=C(O1)C=NN1CCOC1=O
Pharmacology
- Indication
For the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.
- Pharmacodynamics
Furoxone has a broad antibacterial spectrum covering the majority of gastrointestinal tract pathogens including E. coli, staphylococci, Salmonella, Shigella, Proteus, Aerobacter aerogenes, Vibrio cholerae and Giardia lamblia. Its bactericidal activity is based upon its interference with DNA replication and protein production; this antimicrobial action minimizes the development of resistant organisms.
- Mechanism of action
Furazolidone and its related free radical products are believed to bind DNA and induce cross-links. Bacterial DNA is particularly susceptible to this drug leading to high levels of mutations (transitions and transversions) in the bacterial chromosome.
Target Actions Organism ADNA cross-linking/alkylationHuman - Absorption
Radiolabeled drug studies indicate that furazolidone is well absorbed following oral administration
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Furazolidone is rapidly and extensively metabolized; the primary metabolic pathway identified begins with nitro-reduction to the aminofuran derivative. Two major metabolites are produced: 3-amino-2-oxazolidone (AOZ) or beta-hydroxyethylhydrazine (HEH). AOZ is responsible for monoamine oxidase inhibition. Detoxification and elimination of the drug is done primarily by conjugation with glutathione.
- Route of elimination
- Not Available
- Half life
10 minutes
- Clearance
- Not Available
- Toxicity
Reactions to Furoxone have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors.
- Affected organisms
- Microbes (bacteria, parasites)
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine Furazolidone may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Furazolidone. Experimental 3,4-Methylenedioxyamphetamine Furazolidone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine Furazolidone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine. Experimental, Illicit 4-Methoxyamphetamine Furazolidone may increase the hypertensive activities of 4-Methoxyamphetamine. Experimental, Illicit 5-methoxy-N,N-dimethyltryptamine The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Furazolidone. Experimental, Illicit 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline Furazolidone may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. Experimental Abediterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Abediterol. Investigational Acarbose Furazolidone may increase the hypoglycemic activities of Acarbose. Approved, Investigational Acebutolol Furazolidone may increase the hypotensive activities of Acebutolol. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Alaproclate is combined with Furazolidone. Experimental Albiglutide Furazolidone may increase the hypoglycemic activities of Albiglutide. Approved Alfentanil Furazolidone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Alfentanil. Approved, Illicit Aliskiren Furazolidone may increase the hypotensive activities of Aliskiren. Approved, Investigational Almotriptan The metabolism of Almotriptan can be decreased when combined with Furazolidone. Approved, Investigational Alogliptin Furazolidone may increase the hypoglycemic activities of Alogliptin. Approved Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Furazolidone. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Alphaprodine is combined with Furazolidone. Illicit Alprenolol Furazolidone may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Altretamine Altretamine may increase the orthostatic hypotensive activities of Furazolidone. Approved Ambrisentan Furazolidone may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amikacin The risk or severity of adverse effects can be increased when Furazolidone is combined with Amikacin. Approved, Investigational, Vet Approved Amineptine Furazolidone may increase the serotonergic activities of Amineptine. Illicit, Withdrawn Amiodarone Furazolidone may increase the orthostatic hypotensive activities of Amiodarone. Approved, Investigational Amitriptyline Furazolidone may increase the serotonergic activities of Amitriptyline. Approved Amitriptylinoxide Furazolidone may increase the serotonergic activities of Amitriptylinoxide. Approved, Investigational Amlodipine Furazolidone may increase the hypotensive activities of Amlodipine. Approved Amoxapine Furazolidone may increase the serotonergic activities of Amoxapine. Approved Amphetamine Furazolidone may increase the hypertensive activities of Amphetamine. Approved, Illicit, Investigational Apomorphine The metabolism of Apomorphine can be decreased when combined with Furazolidone. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Furazolidone is combined with Apraclonidine. Approved Arbutamine The risk or severity of adverse effects can be increased when Furazolidone is combined with Arbutamine. Approved Arformoterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Arformoterol. Approved, Investigational Atenolol Furazolidone may increase the hypotensive activities of Atenolol. Approved Atomoxetine Furazolidone may increase the central neurotoxic activities of Atomoxetine. Approved Atropine The risk or severity of hypertension can be increased when Furazolidone is combined with Atropine. Approved, Vet Approved Bambuterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Bambuterol. Approved, Investigational Barnidipine Furazolidone may increase the orthostatic hypotensive activities of Barnidipine. Approved Benazepril Furazolidone may increase the hypotensive activities of Benazepril. Approved, Investigational Bendroflumethiazide Furazolidone may increase the hypotensive activities of Bendroflumethiazide. Approved Benmoxin Benmoxin may increase the hypertensive activities of Furazolidone. Withdrawn Benzphetamine Furazolidone may increase the hypertensive activities of Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Furazolidone. Approved Bepridil Furazolidone may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betahistine The serum concentration of Betahistine can be increased when it is combined with Furazolidone. Approved, Investigational Betaxolol Furazolidone may increase the hypotensive activities of Betaxolol. Approved, Investigational Bethanidine Furazolidone may increase the hypotensive activities of Bethanidine. Approved Bezafibrate The risk or severity of adverse effects can be increased when Furazolidone is combined with Bezafibrate. Approved, Investigational Bietaserpine Furazolidone may increase the hypotensive activities of Bietaserpine. Experimental Bimatoprost Furazolidone may increase the hypotensive activities of Bimatoprost. Approved, Investigational Bitolterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Bitolterol. Withdrawn Bosentan Furazolidone may increase the hypotensive activities of Bosentan. Approved, Investigational BQ-123 Furazolidone may increase the hypotensive activities of BQ-123. Investigational Bretylium Furazolidone may increase the hypotensive activities of Bretylium. Approved Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Furazolidone. Approved, Investigational Brimonidine The risk or severity of adverse effects can be increased when Furazolidone is combined with Brimonidine. Approved Brofaromine Furazolidone may increase the hypertensive activities of Brofaromine. Experimental Bromocriptine The metabolism of Bromocriptine can be decreased when combined with Furazolidone. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Furazolidone. Approved Bupranolol Furazolidone may increase the hypotensive activities of Bupranolol. Approved Buprenorphine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Furazolidone. Approved, Illicit, Investigational, Vet Approved Bupropion The risk or severity of adverse effects can be increased when Furazolidone is combined with Bupropion. Approved Buspirone The risk or severity of adverse effects can be increased when Furazolidone is combined with Buspirone. Approved, Investigational Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Furazolidone. Approved, Illicit, Vet Approved Butriptyline Furazolidone may increase the serotonergic activities of Butriptyline. Approved Cabergoline The metabolism of Cabergoline can be decreased when combined with Furazolidone. Approved Cadralazine Furazolidone may increase the hypotensive activities of Cadralazine. Experimental Cafedrine Furazolidone may increase the hypotensive activities of Cafedrine. Investigational Canagliflozin Furazolidone may increase the hypoglycemic activities of Canagliflozin. Approved Candesartan Furazolidone may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil Furazolidone may increase the hypotensive activities of Candesartan cilexetil. Approved Candoxatril Furazolidone may increase the hypotensive activities of Candoxatril. Experimental Captopril Furazolidone may increase the hypotensive activities of Captopril. Approved Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Furazolidone. Approved, Investigational Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Furazolidone. Illicit, Investigational, Vet Approved Cariprazine The metabolism of Cariprazine can be decreased when combined with Furazolidone. Approved, Investigational Caroxazone Caroxazone may increase the hypertensive activities of Furazolidone. Withdrawn Carteolol Furazolidone may increase the hypotensive activities of Carteolol. Approved Carvedilol Furazolidone may increase the hypotensive activities of Carvedilol. Approved, Investigational Celiprolol Furazolidone may increase the hypotensive activities of Celiprolol. Approved, Investigational Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Furazolidone. Approved Chlorothiazide Furazolidone may increase the hypotensive activities of Chlorothiazide. Approved, Vet Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Furazolidone. Approved Chlorphentermine Furazolidone may increase the hypertensive activities of Chlorphentermine. Illicit, Withdrawn Chlorpropamide Furazolidone may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Chlorthalidone Furazolidone may increase the hypotensive activities of Chlorthalidone. Approved Cicletanine Furazolidone may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Furazolidone may increase the hypotensive activities of Cilazapril. Approved Cilnidipine Furazolidone may increase the orthostatic hypotensive activities of Cilnidipine. Approved, Investigational Cinitapride The metabolism of Cinitapride can be decreased when combined with Furazolidone. Approved, Investigational Cirazoline Furazolidone may increase the hypertensive activities of Cirazoline. Experimental Citalopram Furazolidone may increase the serotonergic activities of Citalopram. Approved Clemastine Furazolidone may increase the anticholinergic activities of Clemastine. Approved, Investigational Clenbuterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Clenbuterol. Approved, Investigational, Vet Approved Clevidipine Furazolidone may increase the orthostatic hypotensive activities of Clevidipine. Approved, Investigational Clindamycin The risk or severity of adverse effects can be increased when Furazolidone is combined with Clindamycin. Approved, Vet Approved Clomipramine Furazolidone may increase the serotonergic activities of Clomipramine. Approved, Investigational, Vet Approved Clonidine Furazolidone may increase the hypertensive activities of Clonidine. Approved Cloranolol Furazolidone may increase the hypotensive activities of Cloranolol. Experimental Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Furazolidone. Approved, Illicit Cryptenamine Furazolidone may increase the hypotensive activities of Cryptenamine. Approved Cyclobenzaprine Cyclobenzaprine may increase the serotonergic activities of Furazolidone. Approved Cyclopenthiazide Furazolidone may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclosporine The risk or severity of adverse effects can be increased when Furazolidone is combined with Cyclosporine. Approved, Investigational, Vet Approved Cyclothiazide Furazolidone may increase the hypotensive activities of Cyclothiazide. Approved Cyproheptadine Furazolidone may increase the anticholinergic activities of Cyproheptadine. Approved Dapagliflozin Furazolidone may increase the orthostatic hypotensive activities of Dapagliflozin. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dapoxetine is combined with Furazolidone. Investigational Debrisoquin Furazolidone may increase the hypotensive activities of Debrisoquin. Approved, Investigational Delapril Furazolidone may increase the hypotensive activities of Delapril. Investigational Deserpidine Furazolidone may increase the hypotensive activities of Deserpidine. Approved Desipramine Furazolidone may increase the serotonergic activities of Desipramine. Approved, Investigational Desvenlafaxine Furazolidone may increase the serotonergic activities of Desvenlafaxine. Approved, Investigational Deutetrabenazine The risk or severity of adverse effects can be increased when Furazolidone is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Furazolidone. Approved Dexmethylphenidate Furazolidone may increase the hypertensive activities of Dexmethylphenidate. Approved, Investigational Dexniguldipine Furazolidone may increase the hypotensive activities of Dexniguldipine. Experimental Dextroamphetamine Furazolidone may increase the hypertensive activities of Dextroamphetamine. Approved, Illicit Dextromethorphan The risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Dextromethorphan. Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Furazolidone. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Furazolidone. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Furazolidone. Approved, Investigational Diazoxide Furazolidone may increase the hypotensive activities of Diazoxide. Approved Dibenzepin Furazolidone may increase the serotonergic activities of Dibenzepin. Experimental Diethylnorspermine Furazolidone may increase the hypotensive activities of Diethylnorspermine. Investigational Diethylpropion The risk or severity of adverse effects can be increased when Furazolidone is combined with Diethylpropion. Approved, Illicit Dihydralazine Furazolidone may increase the hypotensive activities of Dihydralazine. Approved, Investigational Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Furazolidone. Approved, Illicit Dihydroergotamine The metabolism of Dihydroergotamine can be decreased when combined with Furazolidone. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Furazolidone. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Furazolidone. Experimental, Illicit Diltiazem Furazolidone may increase the hypotensive activities of Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Furazolidone. Approved Dimetacrine Furazolidone may increase the serotonergic activities of Dimetacrine. Approved, Withdrawn Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Furazolidone. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furazolidone. Approved, Illicit Dipivefrin Furazolidone may increase the hypertensive activities of Dipivefrin. Approved Disopyramide Furazolidone may increase the hypoglycemic activities of Disopyramide. Approved Disulfiram The risk or severity of convulsion can be increased when Furazolidone is combined with Disulfiram. Approved Dobutamine The risk or severity of adverse effects can be increased when Furazolidone is combined with Dobutamine. Approved Domperidone The risk or severity of adverse effects can be increased when Furazolidone is combined with Domperidone. Approved, Investigational, Vet Approved Dorzolamide Furazolidone may increase the hypotensive activities of Dorzolamide. Approved Dosulepin Furazolidone may increase the serotonergic activities of Dosulepin. Approved Dotarizine The risk or severity of adverse effects can be increased when Furazolidone is combined with Dotarizine. Investigational Doxapram Furazolidone may increase the hypertensive activities of Doxapram. Approved, Vet Approved Doxazosin Furazolidone may increase the hypotensive activities of Doxazosin. Approved Doxepin Furazolidone may increase the serotonergic activities of Doxepin. Approved, Investigational Doxofylline The risk or severity of adverse effects can be increased when Furazolidone is combined with Doxofylline. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Furazolidone. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when DPDPE is combined with Furazolidone. Experimental Drotebanol The risk or severity of adverse effects can be increased when Drotebanol is combined with Furazolidone. Experimental, Illicit Droxidopa Furazolidone may increase the hypertensive activities of Droxidopa. Approved, Investigational Dulaglutide Furazolidone may increase the hypoglycemic activities of Dulaglutide. Approved, Investigational Duloxetine Furazolidone may increase the serotonergic activities of Duloxetine. Approved Ecgonine The risk or severity of adverse effects can be increased when Ecgonine is combined with Furazolidone. Experimental, Illicit Efonidipine Furazolidone may increase the hypotensive activities of Efonidipine. Approved, Investigational Eletriptan The metabolism of Eletriptan can be decreased when combined with Furazolidone. Approved, Investigational Empagliflozin Furazolidone may increase the hypoglycemic activities of Empagliflozin. Approved Enalapril Furazolidone may increase the hypotensive activities of Enalapril. Approved, Vet Approved Enalaprilat Furazolidone may increase the hypotensive activities of Enalaprilat. Approved Endralazine Furazolidone may increase the hypotensive activities of Endralazine. Experimental Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Furazolidone. Approved, Investigational Epanolol Furazolidone may increase the hypotensive activities of Epanolol. Experimental Eperisone The risk or severity of adverse effects can be increased when Furazolidone is combined with Eperisone. Approved, Investigational Ephedra The risk or severity of adverse effects can be increased when Furazolidone is combined with Ephedra. Approved, Nutraceutical, Withdrawn Epinephrine Furazolidone may increase the hypertensive activities of Epinephrine. Approved, Vet Approved Epoprostenol Furazolidone may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Furazolidone may increase the hypotensive activities of Eprosartan. Approved Ergonovine Furazolidone may increase the hypertensive activities of Ergonovine. Approved Ergotamine Furazolidone may increase the hypertensive activities of Ergotamine. Approved Escitalopram Furazolidone may increase the serotonergic activities of Escitalopram. Approved, Investigational Etafedrine The risk or severity of adverse effects can be increased when Furazolidone is combined with Etafedrine. Approved Ethanol Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Furazolidone. Approved Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Furazolidone. Approved, Illicit Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Furazolidone. Approved Etoperidone Furazolidone may increase the serotonergic activities of Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Furazolidone. Illicit, Vet Approved Exenatide Furazolidone may increase the hypoglycemic activities of Exenatide. Approved, Investigational Felodipine Furazolidone may increase the hypotensive activities of Felodipine. Approved, Investigational Fenfluramine Furazolidone may increase the serotonergic activities of Fenfluramine. Approved, Illicit, Investigational, Withdrawn Fenoldopam Furazolidone may increase the hypotensive activities of Fenoldopam. Approved Fenoterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Fenoterol. Approved, Investigational Fentanyl The risk or severity of hypertension, serotonin syndrome, and CNS depression can be increased when Furazolidone is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Ferulic acid Furazolidone may increase the hypotensive activities of Ferulic acid. Experimental Flibanserin The metabolism of Flibanserin can be decreased when combined with Furazolidone. Approved, Investigational Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Furazolidone. Approved Fluoxetine Furazolidone may increase the serotonergic activities of Fluoxetine. Approved, Vet Approved Fluspirilene The risk or severity of adverse effects can be increased when Furazolidone is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Furazolidone. Approved Fluvoxamine Furazolidone may increase the serotonergic activities of Fluvoxamine. Approved, Investigational Formoterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Formoterol. Approved, Investigational Fosinopril Furazolidone may increase the hypotensive activities of Fosinopril. Approved Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Furazolidone. Approved, Investigational Furosemide Furazolidone may increase the orthostatic hypotensive activities of Furosemide. Approved, Vet Approved Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Furazolidone. Approved, Investigational Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Furazolidone. Experimental Gliclazide Furazolidone may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Furazolidone may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Furazolidone may increase the hypoglycemic activities of Glipizide. Approved, Investigational Glyburide Furazolidone may increase the hypoglycemic activities of Glyburide. Approved Guanabenz Furazolidone may increase the hypotensive activities of Guanabenz. Approved, Investigational Guanadrel Furazolidone may increase the hypotensive activities of Guanadrel. Approved Guanethidine Furazolidone may increase the hypotensive activities of Guanethidine. Approved Guanfacine Furazolidone may increase the hypotensive activities of Guanfacine. Approved, Investigational Guanoclor Furazolidone may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Furazolidone may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Furazolidone may increase the hypotensive activities of Guanoxan. Experimental Harmaline Furazolidone may increase the hypertensive activities of Harmaline. Experimental Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Furazolidone. Approved, Illicit, Investigational Hexamethonium Furazolidone may increase the hypotensive activities of Hexamethonium. Experimental Hexoprenaline The risk or severity of adverse effects can be increased when Furazolidone is combined with Hexoprenaline. Approved, Withdrawn Hydracarbazine Hydracarbazine may increase the hypertensive activities of Furazolidone. Experimental Hydralazine Furazolidone may increase the hypotensive activities of Hydralazine. Approved Hydrochlorothiazide Furazolidone may increase the hypotensive activities of Hydrochlorothiazide. Approved, Vet Approved Hydrocodone Furazolidone may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydroflumethiazide Furazolidone may increase the hypotensive activities of Hydroflumethiazide. Approved, Investigational Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Furazolidone. Approved, Illicit Hydroxyamphetamine Furazolidone may increase the hypertensive activities of Hydroxyamphetamine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Furazolidone. Approved Imidapril Furazolidone may increase the hypotensive activities of Imidapril. Investigational Imipramine Furazolidone may increase the serotonergic activities of Imipramine. Approved Indacaterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Indacaterol. Approved Indalpine Furazolidone may increase the serotonergic activities of Indalpine. Investigational, Withdrawn Indapamide Furazolidone may increase the hypotensive activities of Indapamide. Approved Indenolol Furazolidone may increase the hypotensive activities of Indenolol. Withdrawn Indoramin Furazolidone may increase the hypotensive activities of Indoramin. Withdrawn Insulin Aspart Furazolidone may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Furazolidone may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Furazolidone may increase the hypoglycemic activities of Insulin Glargine. Approved Insulin Glulisine Furazolidone may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Furazolidone may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Lispro Furazolidone may increase the hypoglycemic activities of Insulin Lispro. Approved Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Furazolidone. Approved Iprindole Furazolidone may increase the serotonergic activities of Iprindole. Experimental Iproclozide Iproclozide may increase the hypertensive activities of Furazolidone. Withdrawn Iproniazid Iproniazid may increase the hypertensive activities of Furazolidone. Withdrawn Irbesartan Furazolidone may increase the hypotensive activities of Irbesartan. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypertensive activities of Furazolidone. Approved Isoetarine The risk or severity of adverse effects can be increased when Furazolidone is combined with Isoetarine. Approved Isometheptene The risk or severity of adverse effects can be increased when Furazolidone is combined with Isometheptene. Approved Isoprenaline The risk or severity of adverse effects can be increased when Furazolidone is combined with Isoprenaline. Approved, Investigational Isosorbide Dinitrate Furazolidone may increase the orthostatic hypotensive activities of Isosorbide Dinitrate. Approved, Investigational Isradipine Furazolidone may increase the hypotensive activities of Isradipine. Approved, Investigational Ketanserin Furazolidone may increase the hypotensive activities of Ketanserin. Investigational Ketobemidone The risk or severity of adverse effects can be increased when Ketobemidone is combined with Furazolidone. Approved, Investigational L-Tryptophan The risk or severity of adverse effects can be increased when L-Tryptophan is combined with Furazolidone. Approved, Nutraceutical, Withdrawn Labetalol Furazolidone may increase the hypotensive activities of Labetalol. Approved Lacidipine Furazolidone may increase the hypotensive activities of Lacidipine. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Furazolidone. Approved, Investigational Latanoprost Furazolidone may increase the hypotensive activities of Latanoprost. Approved, Investigational Lercanidipine Furazolidone may increase the hypotensive activities of Lercanidipine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Furazolidone. Approved, Investigational Levodopa Furazolidone may increase the orthostatic hypotensive activities of Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Furazolidone. Approved, Investigational Levomilnacipran Furazolidone may increase the serotonergic activities of Levomilnacipran. Approved, Investigational Levonordefrin Furazolidone may increase the hypertensive activities of Levonordefrin. Approved Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Furazolidone. Approved Levosalbutamol The risk or severity of adverse effects can be increased when Furazolidone is combined with Levosalbutamol. Approved, Investigational Linezolid The risk or severity of adverse effects can be increased when Furazolidone is combined with Linezolid. Approved, Investigational Linsidomine Furazolidone may increase the hypotensive activities of Linsidomine. Experimental Liraglutide Furazolidone may increase the hypoglycemic activities of Liraglutide. Approved Lisdexamfetamine Furazolidone may increase the hypertensive activities of Lisdexamfetamine. Approved, Investigational Lisinopril Furazolidone may increase the hypotensive activities of Lisinopril. Approved, Investigational Lisuride The metabolism of Lisuride can be decreased when combined with Furazolidone. Approved, Investigational Lithium cation The risk or severity of adverse effects can be increased when Furazolidone is combined with Lithium. Experimental Lofentanil The risk or severity of adverse effects can be increased when Lofentanil is combined with Furazolidone. Illicit Lofepramine Furazolidone may increase the serotonergic activities of Lofepramine. Experimental Lofexidine The metabolism of Lofexidine can be decreased when combined with Furazolidone. Approved, Investigational Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Furazolidone. Approved, Investigational Lorpiprazole The risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Furazolidone. Approved Losartan Furazolidone may increase the hypotensive activities of Losartan. Approved Macitentan Furazolidone may increase the hypotensive activities of Macitentan. Approved Magnesium carbonate The risk or severity of adverse effects can be increased when Furazolidone is combined with Magnesium carbonate. Approved, Investigational Magnesium citrate The risk or severity of adverse effects can be increased when Furazolidone is combined with Magnesium citrate. Approved Magnesium hydroxide The risk or severity of adverse effects can be increased when Furazolidone is combined with Magnesium hydroxide. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Furazolidone can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate The risk or severity of adverse effects can be increased when Furazolidone is combined with Magnesium Trisilicate. Approved Manidipine Furazolidone may increase the hypotensive activities of Manidipine. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Furazolidone is combined with Maprotiline. Approved, Investigational Mebanazine Mebanazine may increase the hypertensive activities of Furazolidone. Withdrawn Mecamylamine Furazolidone may increase the hypotensive activities of Mecamylamine. Approved, Investigational Mecasermin Furazolidone may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Furazolidone. Approved Melitracen Furazolidone may increase the serotonergic activities of Melitracen. Experimental, Investigational Mephedrone Furazolidone may increase the hypertensive activities of Mephedrone. Investigational Mephentermine Furazolidone may increase the hypertensive activities of Mephentermine. Approved Meptazinol The risk or severity of adverse effects can be increased when Meptazinol is combined with Furazolidone. Experimental Mequitazine Furazolidone may increase the anticholinergic activities of Mequitazine. Approved Metaraminol Furazolidone may increase the hypertensive activities of Metaraminol. Approved, Investigational Metformin Furazolidone may increase the hypoglycemic activities of Metformin. Approved Methadone The risk or severity of adverse effects can be increased when Furazolidone is combined with Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Furazolidone. Approved, Illicit Methamphetamine Furazolidone may increase the hypertensive activities of Methamphetamine. Approved, Illicit Methoserpidine Furazolidone may increase the hypotensive activities of Methoserpidine. Experimental Methoxamine Furazolidone may increase the hypertensive activities of Methoxamine. Approved, Investigational Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Furazolidone. Experimental Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Furazolidone. Approved Methyldopa The risk or severity of hypertension can be increased when Furazolidone is combined with Methyldopa. Approved Methylecgonine The risk or severity of adverse effects can be increased when Methylecgonine is combined with Furazolidone. Experimental Methylene blue Furazolidone may increase the serotonergic activities of Methylene blue. Approved, Investigational Methylphenidate Furazolidone may increase the hypertensive activities of Methylphenidate. Approved, Investigational Methysergide The metabolism of Methysergide can be decreased when combined with Furazolidone. Approved Metipranolol Furazolidone may increase the hypotensive activities of Metipranolol. Approved Metoclopramide The risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Metoclopramide. Approved, Investigational Metolazone Furazolidone may increase the hypotensive activities of Metolazone. Approved Metoprolol Furazolidone may increase the hypotensive activities of Metoprolol. Approved, Investigational Metyrosine Furazolidone may increase the hypotensive activities of Metyrosine. Approved Mianserin The risk or severity of adverse effects can be increased when Furazolidone is combined with Mianserin. Approved, Investigational Mibefradil Furazolidone may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Midodrine Furazolidone may increase the hypertensive activities of Midodrine. Approved Midomafetamine Furazolidone may increase the hypertensive activities of Midomafetamine. Experimental, Illicit, Investigational Mifepristone Furazolidone may increase the hypoglycemic activities of Mifepristone. Approved, Investigational Miglitol Furazolidone may increase the hypoglycemic activities of Miglitol. Approved Milnacipran Furazolidone may increase the serotonergic activities of Milnacipran. Approved, Investigational Minaprine Minaprine may increase the hypertensive activities of Furazolidone. Approved Minoxidil Furazolidone may increase the hypotensive activities of Minoxidil. Approved, Investigational Mirtazapine The risk or severity of adverse effects can be increased when Furazolidone is combined with Mirtazapine. Approved MMDA Furazolidone may increase the hypertensive activities of MMDA. Experimental, Illicit Moclobemide The risk or severity of adverse effects can be increased when Furazolidone is combined with Moclobemide. Approved, Investigational Moexipril Furazolidone may increase the hypotensive activities of Moexipril. Approved Morphine The therapeutic efficacy of Morphine can be increased when used in combination with Furazolidone. Approved, Investigational Moxonidine Furazolidone may increase the hypotensive activities of Moxonidine. Approved, Investigational Muzolimine Furazolidone may increase the hypotensive activities of Muzolimine. Experimental Nadolol Furazolidone may increase the hypotensive activities of Nadolol. Approved Naftopidil Furazolidone may increase the hypotensive activities of Naftopidil. Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Furazolidone. Approved Naluzotan The metabolism of Naluzotan can be decreased when combined with Furazolidone. Investigational Naphazoline Furazolidone may increase the hypertensive activities of Naphazoline. Approved Naratriptan The metabolism of Naratriptan can be decreased when combined with Furazolidone. Approved, Investigational Nateglinide Furazolidone may increase the hypoglycemic activities of Nateglinide. Approved, Investigational Nebivolol Furazolidone may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone Furazolidone may increase the serotonergic activities of Nefazodone. Approved, Withdrawn Neomycin The risk or severity of adverse effects can be increased when Furazolidone is combined with Neomycin. Approved, Vet Approved Nialamide Nialamide may increase the hypertensive activities of Furazolidone. Withdrawn Nicardipine Furazolidone may increase the hypotensive activities of Nicardipine. Approved, Investigational Nicorandil Furazolidone may increase the hypotensive activities of Nicorandil. Approved, Investigational Nifedipine Furazolidone may increase the orthostatic hypotensive activities of Nifedipine. Approved Niguldipine Furazolidone may increase the hypotensive activities of Niguldipine. Experimental Nilvadipine Furazolidone may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimodipine Furazolidone may increase the hypotensive activities of Nimodipine. Approved, Investigational Nisoldipine Furazolidone may increase the hypotensive activities of Nisoldipine. Approved Nitrendipine Furazolidone may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nitroprusside Furazolidone may increase the hypotensive activities of Nitroprusside. Approved, Investigational Norepinephrine Furazolidone may increase the hypertensive activities of Norepinephrine. Approved Normethadone The risk or severity of adverse effects can be increased when Normethadone is combined with Furazolidone. Approved, Illicit Nortriptyline Furazolidone may increase the serotonergic activities of Nortriptyline. Approved Octamoxin Octamoxin may increase the hypertensive activities of Furazolidone. Withdrawn Olanzapine Furazolidone may increase the serotonergic activities of Olanzapine. Approved, Investigational Olmesartan Furazolidone may increase the hypotensive activities of Olmesartan. Approved, Investigational Olodaterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Olodaterol. Approved Omapatrilat Furazolidone may increase the hypotensive activities of Omapatrilat. Investigational Ondansetron The risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Furazolidone. Approved Opipramol Furazolidone may increase the serotonergic activities of Opipramol. Investigational Opium The risk or severity of adverse effects can be increased when Opium is combined with Furazolidone. Approved, Illicit Orciprenaline The risk or severity of adverse effects can be increased when Furazolidone is combined with Orciprenaline. Approved Oxprenolol Furazolidone may increase the hypotensive activities of Oxprenolol. Approved Oxycodone Furazolidone may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone. Approved, Illicit, Investigational Oxymetazoline Furazolidone may increase the hypertensive activities of Oxymetazoline. Approved, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Furazolidone. Approved, Investigational, Vet Approved Pargyline Pargyline may increase the hypertensive activities of Furazolidone. Approved Paromomycin The risk or severity of adverse effects can be increased when Furazolidone is combined with Paromomycin. Approved, Investigational Paroxetine Furazolidone may increase the serotonergic activities of Paroxetine. Approved, Investigational Penbutolol Furazolidone may increase the hypotensive activities of Penbutolol. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Penfluridol is combined with Furazolidone. Experimental Pentamidine Furazolidone may increase the hypoglycemic activities of Pentamidine. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Furazolidone. Approved, Vet Approved Pentolinium Furazolidone may increase the hypotensive activities of Pentolinium. Approved Pergolide The metabolism of Pergolide can be decreased when combined with Furazolidone. Approved, Investigational, Vet Approved, Withdrawn Perindopril Furazolidone may increase the hypotensive activities of Perindopril. Approved Pethidine Furazolidone may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine. Approved PF-00610355 The risk or severity of adverse effects can be increased when Furazolidone is combined with PF-00610355. Investigational Phenazocine The risk or severity of adverse effects can be increased when Phenazocine is combined with Furazolidone. Experimental Phendimetrazine Furazolidone may increase the hypertensive activities of Phendimetrazine. Approved, Illicit Phenelzine Phenelzine may increase the hypertensive activities of Furazolidone. Approved Pheniprazine Pheniprazine may increase the hypertensive activities of Furazolidone. Withdrawn Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Furazolidone. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Phenoperidine is combined with Furazolidone. Experimental Phenoxybenzamine Furazolidone may increase the hypotensive activities of Phenoxybenzamine. Approved Phenoxypropazine Phenoxypropazine may increase the hypertensive activities of Furazolidone. Withdrawn Phentermine Furazolidone may increase the hypertensive activities of Phentermine. Approved, Illicit Phentolamine Furazolidone may increase the hypotensive activities of Phentolamine. Approved Phenylephrine Furazolidone may increase the hypertensive activities of Phenylephrine. Approved Phenylpropanolamine The risk or severity of adverse effects can be increased when Furazolidone is combined with Phenylpropanolamine. Approved, Vet Approved, Withdrawn Pholcodine Pholcodine may increase the serotonergic activities of Furazolidone. Approved, Illicit Piclozotan The metabolism of Piclozotan can be decreased when combined with Furazolidone. Investigational Pinacidil Furazolidone may increase the hypotensive activities of Pinacidil. Approved Pindolol Furazolidone may increase the hypotensive activities of Pindolol. Approved, Investigational Pioglitazone Furazolidone may increase the hypoglycemic activities of Pioglitazone. Approved, Investigational Pirbuterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Pirbuterol. Approved Piritramide The risk or severity of adverse effects can be increased when Piritramide is combined with Furazolidone. Approved, Investigational Pirlindole Pirlindole may increase the hypertensive activities of Furazolidone. Approved Pivhydrazine Pivhydrazine may increase the hypertensive activities of Furazolidone. Withdrawn Pizotifen Furazolidone may increase the anticholinergic activities of Pizotifen. Approved Platelet Activating Factor Furazolidone may increase the hypotensive activities of Platelet Activating Factor. Experimental Polymyxin B Sulfate The risk or severity of adverse effects can be increased when Furazolidone is combined with Polymyxin B Sulfate. Approved, Vet Approved Polythiazide Furazolidone may increase the hypotensive activities of Polythiazide. Approved Pramipexole Furazolidone may increase the sedative activities of Pramipexole. Approved, Investigational Pramlintide Furazolidone may increase the hypoglycemic activities of Pramlintide. Approved, Investigational Prazosin Furazolidone may increase the hypotensive activities of Prazosin. Approved Pregabalin The therapeutic efficacy of Furazolidone can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Procaine Furazolidone may increase the hypertensive activities of Procaine. Approved, Investigational, Vet Approved Procarbazine Furazolidone may increase the hypertensive activities of Procarbazine. Approved, Investigational Procaterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Procaterol. Approved, Investigational Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Furazolidone. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Furazolidone. Approved, Investigational Propranolol Furazolidone may increase the hypotensive activities of Propranolol. Approved, Investigational Protokylol The risk or severity of adverse effects can be increased when Furazolidone is combined with Protokylol. Approved, Vet Approved Protriptyline Furazolidone may increase the serotonergic activities of Protriptyline. Approved Pseudoephedrine Furazolidone may increase the hypertensive activities of Pseudoephedrine. Approved Pyrantel The risk or severity of adverse effects can be increased when Furazolidone is combined with Pyrantel. Approved, Vet Approved Quetiapine Furazolidone may increase the orthostatic hypotensive activities of Quetiapine. Approved Quinapril Furazolidone may increase the hypotensive activities of Quinapril. Approved, Investigational Quinine Furazolidone may increase the hypoglycemic activities of Quinine. Approved Racepinephrine Furazolidone may increase the hypertensive activities of Racepinephrine. Approved Ramipril Furazolidone may increase the hypotensive activities of Ramipril. Approved Rasagiline Rasagiline may increase the hypertensive activities of Furazolidone. Approved Remifentanil Furazolidone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Remifentanil. Approved Remikiren Furazolidone may increase the hypotensive activities of Remikiren. Approved Repaglinide Furazolidone may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Rescinnamine Furazolidone may increase the hypotensive activities of Rescinnamine. Approved Reserpine The risk or severity of adverse effects can be increased when Furazolidone is combined with Reserpine. Approved, Investigational Rilmenidine Furazolidone may increase the hypotensive activities of Rilmenidine. Approved, Investigational Riociguat Furazolidone may increase the hypotensive activities of Riociguat. Approved Ritobegron Furazolidone may increase the hypertensive activities of Ritobegron. Investigational Ritodrine The risk or severity of adverse effects can be increased when Furazolidone is combined with Ritodrine. Approved, Investigational Rizatriptan The metabolism of Rizatriptan can be decreased when combined with Furazolidone. Approved Ropinirole Furazolidone may increase the sedative activities of Ropinirole. Approved, Investigational Rosiglitazone Furazolidone may increase the hypoglycemic activities of Rosiglitazone. Approved, Investigational Rotigotine The metabolism of Rotigotine can be decreased when combined with Furazolidone. Approved Safrazine Safrazine may increase the hypertensive activities of Furazolidone. Withdrawn Salbutamol The risk or severity of adverse effects can be increased when Furazolidone is combined with Salbutamol. Approved, Vet Approved Salmeterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Salmeterol. Approved Saprisartan Furazolidone may increase the hypotensive activities of Saprisartan. Experimental Saxagliptin Furazolidone may increase the hypoglycemic activities of Saxagliptin. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Furazolidone. Approved, Investigational Selegiline Selegiline may increase the hypertensive activities of Furazolidone. Approved, Investigational, Vet Approved Selexipag Furazolidone may increase the hypotensive activities of Selexipag. Approved Sertraline Furazolidone may increase the serotonergic activities of Sertraline. Approved Sitagliptin Furazolidone may increase the hypoglycemic activities of Sitagliptin. Approved, Investigational Sitaxentan Furazolidone may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Spirapril Furazolidone may increase the hypotensive activities of Spirapril. Approved Spironolactone Furazolidone may increase the orthostatic hypotensive activities of Spironolactone. Approved Sufentanil Furazolidone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil. Approved, Investigational Sulfadiazine Furazolidone may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole Furazolidone may increase the hypoglycemic activities of Sulfamethoxazole. Approved Sulfisoxazole Furazolidone may increase the hypoglycemic activities of Sulfisoxazole. Approved, Vet Approved Sumatriptan The metabolism of Sumatriptan can be decreased when combined with Furazolidone. Approved, Investigational Sunitinib Furazolidone may increase the hypoglycemic activities of Sunitinib. Approved, Investigational Talinolol Furazolidone may increase the hypotensive activities of Talinolol. Investigational Tapentadol The risk or severity of adverse effects can be increased when Tapentadol is combined with Furazolidone. Approved Telmisartan Furazolidone may increase the hypotensive activities of Telmisartan. Approved, Investigational Temocapril Furazolidone may increase the hypotensive activities of Temocapril. Experimental, Investigational Terbutaline The risk or severity of adverse effects can be increased when Furazolidone is combined with Terbutaline. Approved Terlipressin Furazolidone may increase the hypotensive activities of Terlipressin. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Furazolidone is combined with Tetrabenazine. Approved, Investigational Tetracycline The risk or severity of adverse effects can be increased when Furazolidone is combined with Tetracycline. Approved, Vet Approved Tetrahydrocannabivarin The metabolism of Tetrahydrocannabivarin can be decreased when combined with Furazolidone. Investigational Tetrahydropalmatine Furazolidone may increase the hypotensive activities of Tetrahydropalmatine. Investigational Tetryzoline Furazolidone may increase the hypertensive activities of Tetryzoline. Approved Theodrenaline Furazolidone may increase the hypotensive activities of Theodrenaline. Investigational Tianeptine The risk or severity of adverse effects can be increased when Tianeptine is combined with Furazolidone. Approved, Investigational Tibolone Furazolidone may increase the hypotensive activities of Tibolone. Approved, Investigational Ticrynafen Furazolidone may increase the hypotensive activities of Ticrynafen. Withdrawn Tilidine The risk or severity of adverse effects can be increased when Tilidine is combined with Furazolidone. Experimental Timolol Furazolidone may increase the hypotensive activities of Timolol. Approved Tolazamide Furazolidone may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolazoline Furazolidone may increase the hypotensive activities of Tolazoline. Approved, Vet Approved Tolbutamide Furazolidone may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Furazolidone. Approved, Withdrawn Tolonidine Furazolidone may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypertensive activities of Furazolidone. Approved Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Furazolidone. Approved Torasemide Furazolidone may increase the hypotensive activities of Torasemide. Approved Tramadol The risk or severity of serotonin syndrome and seizure can be increased when Furazolidone is combined with Tramadol. Approved, Investigational Trandolapril Furazolidone may increase the hypotensive activities of Trandolapril. Approved Tranylcypromine Tranylcypromine may increase the hypertensive activities of Furazolidone. Approved, Investigational Travoprost Furazolidone may increase the hypotensive activities of Travoprost. Approved Trazodone Furazolidone may increase the serotonergic activities of Trazodone. Approved, Investigational Treprostinil Furazolidone may increase the hypotensive activities of Treprostinil. Approved, Investigational Trichlormethiazide Furazolidone may increase the hypotensive activities of Trichlormethiazide. Approved, Vet Approved Trimazosin Furazolidone may increase the hypotensive activities of Trimazosin. Experimental Trimethadione The risk or severity of adverse effects can be increased when Furazolidone is combined with Trimethadione. Approved Trimethaphan Furazolidone may increase the hypotensive activities of Trimethaphan. Approved, Investigational Trimipramine Furazolidone may increase the serotonergic activities of Trimipramine. Approved Unoprostone Furazolidone may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Furazolidone may increase the hypotensive activities of Urapidil. Investigational Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Furazolidone. Approved, Investigational Valsartan Furazolidone may increase the hypotensive activities of Valsartan. Approved, Investigational Vancomycin The risk or severity of adverse effects can be increased when Furazolidone is combined with Vancomycin. Approved Vecuronium The risk or severity of adverse effects can be increased when Furazolidone is combined with Vecuronium. Approved Venlafaxine Furazolidone may increase the serotonergic activities of Venlafaxine. Approved Verapamil Furazolidone may increase the orthostatic hypotensive activities of Verapamil. Approved Vilanterol The risk or severity of adverse effects can be increased when Furazolidone is combined with Vilanterol. Approved Vilazodone The metabolism of Vilazodone can be decreased when combined with Furazolidone. Approved Vincamine Furazolidone may increase the hypotensive activities of Vincamine. Experimental Vinpocetine The risk or severity of adverse effects can be increased when Furazolidone is combined with Vinpocetine. Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Furazolidone. Approved, Investigational Xipamide Furazolidone may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Furazolidone may increase the hypertensive activities of Xylometazoline. Approved, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Furazolidone. Approved Zimelidine Furazolidone may increase the serotonergic activities of Zimelidine. Withdrawn Ziprasidone The metabolism of Ziprasidone can be decreased when combined with Furazolidone. Approved Zofenopril Furazolidone may increase the hypotensive activities of Zofenopril. Experimental Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Furazolidone. Approved, Investigational Zolpidem Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Furazolidone. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company.
US2742462- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014752
- KEGG Drug
- D00830
- KEGG Compound
- C07999
- PubChem Compound
- 3435
- PubChem Substance
- 46507291
- ChemSpider
- 4481255
- ChEBI
- 5195
- ChEMBL
- CHEMBL1103
- Therapeutic Targets Database
- DAP000993
- PharmGKB
- PA164746760
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Furazolidone
- ATC Codes
- G01AX06 — Furazolidone
- MSDS
- Download (74.1 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Functional Dyspepsia / Scarred Peptic Ulcer 1 4 Not Yet Recruiting Treatment Antimicrobial Susceptibility Testing / Bacterial Infection Due to Helicobacter Pylori (H. Pylori) 1 4 Not Yet Recruiting Treatment Antimicrobial Susceptibility Testing / Triple Therapy 1 4 Not Yet Recruiting Treatment Bacterial Infection Due to Helicobacter Pylori (H. Pylori) 1 4 Not Yet Recruiting Treatment Bacterial Infection Due to Helicobacter Pylori (H. Pylori) / Gastric Ulcer (GU) / Gastritis / Gastritis Chronic / Malignant Neoplasm of Stomach 1 4 Recruiting Treatment Antimicrobial Susceptibility Testing / Bacterial Infection Due to Helicobacter Pylori (H. Pylori) 1 4 Recruiting Treatment Bacterial Infection Due to Helicobacter Pylori (H. Pylori) 1 4 Recruiting Treatment Duodenal Ulcer Due to Helicobacter Pylori 1 Not Available Completed Treatment Treatment of Helicobacter Pylori 1
Pharmacoeconomics
- Manufacturers
- Shire development inc
- Packagers
- Professional Co.
- Dosage forms
- Not Available
- Prices
Unit description Cost Unit Furazolidone powder 2.04USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 254-256 Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company water solubility 40 mg/L (at 25 °C) MERCK INDEX (1996); pH 6 logP -0.04 DEBNATH,AK ET AL. (1991) - Predicted Properties
Property Value Source Water Solubility 0.364 mg/mL ALOGPS logP 0.15 ALOGPS logP 0.87 ChemAxon logS -2.8 ALOGPS pKa (Strongest Basic) -2.4 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 100.86 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 51.09 m3·mol-1 ChemAxon Polarizability 19.74 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9038 Blood Brain Barrier + 0.9117 Caco-2 permeable - 0.5736 P-glycoprotein substrate Non-substrate 0.7829 P-glycoprotein inhibitor I Non-inhibitor 0.7761 P-glycoprotein inhibitor II Non-inhibitor 0.9597 Renal organic cation transporter Non-inhibitor 0.8351 CYP450 2C9 substrate Non-substrate 0.8117 CYP450 2D6 substrate Non-substrate 0.8415 CYP450 3A4 substrate Substrate 0.5984 CYP450 1A2 substrate Inhibitor 0.9107 CYP450 2C9 inhibitor Non-inhibitor 0.907 CYP450 2D6 inhibitor Non-inhibitor 0.9134 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.928 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8828 Ames test AMES toxic 0.9108 Carcinogenicity Non-carcinogens 0.9097 Biodegradation Ready biodegradable 0.8978 Rat acute toxicity 2.1639 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7889 hERG inhibition (predictor II) Non-inhibitor 0.9057
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as nitrofurans. These are compounds containing a furan ring which bears a nitro group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Furans
- Sub Class
- Nitrofurans
- Direct Parent
- Nitrofurans
- Alternative Parents
- Nitroaromatic compounds / Oxazolidinones / Heteroaromatic compounds / Organic carbonic acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds show 3 more
- Substituents
- Nitroaromatic compound / 2-nitrofuran / Oxazolidinone / Oxazolidine / Heteroaromatic compound / C-nitro compound / Carbonic acid derivative / Organic nitro compound / Organic oxoazanium / Allyl-type 1,3-dipolar organic compound show 13 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- oxazolidines, nitrofuran antibiotic (CHEBI:5195)
Targets
1. DNA
Yes
Cross-linking/alkylation
- General Function:
- Used for biological information storage.
- Specific Function:
- DNA contains the instructions needed for an organism to develop, survive and reproduce.
- Molecular Weight:
- 2.15 x 1012 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Meng J, Mangat SS, Grudzinski IP, Law FC: Evidence of 14C-furazolidone metabolite binding to the hepatic DNA of trout. Drug Metabol Drug Interact. 1998;14(4):209-19. [PubMed:10694929]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Primary amine oxidase activity
- Specific Function
- Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
- Gene Name
- MAOB
- Uniprot ID
- P27338
- Uniprot Name
- Amine oxidase [flavin-containing] B
- Molecular Weight
- 58762.475 Da
References
- Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758]
- Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364]
- Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Serotonin binding
- Specific Function
- Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
- Gene Name
- MAOA
- Uniprot ID
- P21397
- Uniprot Name
- Amine oxidase [flavin-containing] A
- Molecular Weight
- 59681.27 Da
References
- Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758]
- Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364]
- Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659]
Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:24